Document 0333
 DOCN  M9590333
 TI    The safety and efficacy of sorivudine (BV-araU) for the treatment of
       zoster in HIV-infected adults: results of a multinational acyclovir
       controlled trial.
 DT    9509
 AU    Boag F; Bodsworth NJ; Burdge D; Genereux M; Barleffs JC; Evans B;
       Colebunders R; Modai J; Thomas M; Marcoccia J; et al; Kobler Centre,
       London.
 SO    Annu Conf Australas Soc HIV Med. 1994 Nov 3-6;6:166 (unnumbered
       abstract). Unique Identifier : AIDSLINE ASHM6/95291766
 AB    Sorivudine (BV-araU) 40mg once daily was compared in a randomised
       double-blind trial to acyclovir 800mg five times daily for seven days
       for the treatment of acute localised zoster in HIV infected adults.
       Patients were seen daily until 100% crusting and on days 7,10,14 and 28
       for assessment of lesion evolution and acute neuritis. In August 1993,
       accrual to the trial was stopped at 137 subjects (of a planned 160) when
       the second interim analysis of the first 112 patients revealed that the
       primary efficacy endpoint (cessation of new lesion formation) had been
       met at p < 0.0151 according to the stopping rules of O'Brien and
       Fleming. TABULAR DATA, SEE ABSTRACT VOLUME. Sorivudine treatment was
       also associated with less frequent analgesic use (p = 0.023) and
       activity impairment (p = 0.042) during the acute phase (Wei-Lachin
       test). All significant differences remained so following adjustment for
       differences in baseline variables and when only evaluable subjects (n =
       113) were included. 12 month follow-up data on PHN remains blinded.
       Sorivudine therapy was safe and well tolerated in this population. When
       compared to acyclovir significant advantages were observed in time to
       cessation of new vesicle formation; 100% crusting; analgesia use and
       activity impairment.
 DE    Acyclovir/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS  Adult  Antiviral
       Agents/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS
       Arabinofuranosyluracil/*ANALOGS & DERIVATIVES/ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS  AIDS-Related Opportunistic Infections/*DRUG
       THERAPY  Comparative Study  Dose-Response Relationship, Drug
       Double-Blind Method  Drug Administration Schedule  Herpes Zoster/*DRUG
       THERAPY  Human  Pain Measurement  Treatment Outcome  CLINICAL TRIAL
       MEETING ABSTRACT  RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).